{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:01:22Z","timestamp":1792065682646,"version":"4.4.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.trre.2017.10.001","type":"journal-article","created":{"date-parts":[[2017,11,4]],"date-time":"2017-11-04T04:31:37Z","timestamp":1509769897000},"page":"58-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["De novo thrombotic microangiopathy after kidney transplantation"],"prefix":"10.1016","volume":"32","author":[{"given":"Neetika","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut G.","family":"Rennke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1032-0801","authenticated-orcid":false,"given":"Martha","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kambiz","family":"Zandi-Nejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2017.10.001_bb0005","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ajkd.2003.07.008","article-title":"Thrombotic microangiopathy after renal transplantation in the United States","volume":"42","author":"Reynolds","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2017.10.001_bb0010","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/ndt\/gft220","article-title":"Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature","volume":"28","author":"Manenti","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0015","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1600-6143.2010.03156.x","article-title":"Thrombotic microangiopathy after kidney transplantation","volume":"10","author":"Noris","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0020","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2017.10.001_bb0025","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2215\/CJN.00050505","article-title":"Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background","volume":"1","author":"Bresin","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0035","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/BF00856651","article-title":"Renal transplantation in patients with classical haemolytic-uraemic syndrome","volume":"5","author":"Bassani","year":"1991","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0040","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s00467-003-1289-8","article-title":"The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children","volume":"18","author":"Loirat","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0045","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00467-002-0936-9","article-title":"Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation","volume":"17","author":"Ferraris","year":"2002","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0050","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/jth.12826","article-title":"Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity","volume":"13","author":"Zafrani","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.trre.2017.10.001_bb0055","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1471-2369-14-156","article-title":"Long term follow up of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) on hemodialysis for 19years: a case report","volume":"14","author":"Mise","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0060","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.trre.2017.10.001_bb0065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/nep.12217","article-title":"Antiphospholipid syndrome in renal transplantation","volume":"19","author":"Barbour","year":"2014","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.trre.2017.10.001_bb0070","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/ajt.12319","article-title":"Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes","volume":"13","author":"Canaud","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0075","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/00007890-200203150-00017","article-title":"De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination","volume":"73","author":"Langer","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.10.001_bb0080","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/ajkd.2003.50058","article-title":"De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy","volume":"41","author":"Schwimmer","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2017.10.001_bb0085","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1046\/j.1523-1755.1999.00492.x","article-title":"Cyclosporine-associated thrombotic microangiopathy in renal allografts","volume":"55","author":"Zarifian","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2017.10.001_bb0090","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1111\/j.1600-6143.2010.03178.x","article-title":"De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection","volume":"10","author":"Satoskar","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0095","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation","volume":"8","author":"Le Quintrec","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0100","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/ctr.12453","article-title":"Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients","volume":"28","author":"Mulgaonkar","year":"2014","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0272-6386(89)80032-0","article-title":"Renal vascular and thrombotic effects of cyclosporine","volume":"13","author":"Remuzzi","year":"1989","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2017.10.001_bb0110","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000020664","article-title":"Role of intrarenal endothelin 1, endothelin 3, and angiotensin II expression in chronic cyclosporin A nephrotoxicity in rats","volume":"8","author":"Ramirez","year":"2000","journal-title":"Exp Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0115","first-page":"218","article-title":"The effect of calcineurin inhibitors on endothelial and platelet function in renal transplant patients","volume":"76","author":"Sahin","year":"2011","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0120","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/ndt\/gfl836","article-title":"Cyclosporine enhances platelet procoagulant activity","volume":"22","author":"Tomasiak","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0125","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/oxfordjournals.ndt.a027265","article-title":"Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients","volume":"11","author":"Verpooten","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0130","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1681\/ASN.2012111064","article-title":"Cyclosporine induces endothelial cell release of complement-activating microparticles","volume":"24","author":"Renner","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0135","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1111\/j.1600-6143.2005.01047.x","article-title":"Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys","volume":"5","author":"Sartelet","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0140","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/j.1600-6143.2006.01433.x","article-title":"mTOR inhibition induces endothelial progenitor cell death","volume":"6","author":"Miriuka","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0145","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1172\/JCI86418","article-title":"VEGF regulates local inhibitory complement proteins in the eye and kidney","volume":"127","author":"Keir","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trre.2017.10.001_bb0150","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1093\/ndt\/gfl340","article-title":"Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy","volume":"21","author":"Keller","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0155","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.thromres.2013.07.004","article-title":"Treatment with everolimus is associated with a procoagulant state","volume":"132","author":"Baas","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.trre.2017.10.001_bb0160","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1600-6143.2004.00428.x","article-title":"Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination","volume":"4","author":"Fortin","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0165","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/ndt\/gfh334","article-title":"De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases","volume":"20","author":"Crew","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0170","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0175","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1034\/j.1600-6143.2003.00051.x","article-title":"Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?","volume":"3","author":"Robson","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0180","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.transproceed.2014.07.062","article-title":"Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation","volume":"46","author":"Nava","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2017.10.001_bb0185","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1034\/j.1600-6143.2003.00072.x","article-title":"Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection","volume":"3","author":"Racusen","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0190","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1600-6143.2011.03926.x","article-title":"Banff 2011 Meeting report: new concepts in antibody-mediated rejection","volume":"12","author":"Mengel","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0195","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2215\/CJN.05870710","article-title":"Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies","volume":"6","author":"Meehan","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0200","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/ctr.12645","article-title":"The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy","volume":"30","author":"Wu","year":"2016","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0205","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1681\/ASN.V101146","article-title":"Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients","volume":"10","author":"Baid","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0210","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ki.2011.194","article-title":"Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy","volume":"80","author":"Baid-Agrawal","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2017.10.001_bb0215","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.transproceed.2011.11.052","article-title":"Spectrum of cytomegalovirus-induced renal pathology in renal allograft recipients","volume":"44","author":"Rane","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2017.10.001_bb0220","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1159\/000321328","article-title":"De novo thrombotic microangiopathy induced by cytomegalovirus infection leading to renal allograft loss","volume":"32","author":"De Keyzer","year":"2010","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0225","first-page":"137","article-title":"Parvovirus B19 microepidemic in renal transplant recipients with thrombotic microangiopathy and allograft vasculitis","volume":"6","author":"Ardalan","year":"2008","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0230","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/ncpneph0609","article-title":"Parvovirus-B19-associated complications in renal transplant recipients","volume":"3","author":"Waldman","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0235","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa010319","article-title":"BK-related polyomavirus vasculopathy in a renal-transplant recipient","volume":"345","author":"Petrogiannis-Haliotis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2017.10.001_bb0240","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/TP.0b013e31818747d8","article-title":"Transplantation-related thrombotic microangiopathy triggered by preemptive therapy for hepatitis C virus infection","volume":"86","author":"Yamazaki","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.10.001_bb0245","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2215\/CJN.03930907","article-title":"Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients","volume":"3","author":"Leca","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0250","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1537-2995.2006.00873.x","article-title":"Disseminated histoplasmosis presenting as thrombotic microangiopathy","volume":"46","author":"Dwyre","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.trre.2017.10.001_bb0255","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/j.ajkd.2004.11.026","article-title":"Acute renal failure in a renal allograft: an unusual infectious cause of thrombotic microangiopathy","volume":"46","author":"Sethi","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2017.10.001_bb0260","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/00007890-200210270-00003","article-title":"Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient","volume":"74","author":"Pham","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.10.001_bb0265","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1111\/j.1600-6143.2006.01574.x","article-title":"From humoral rejection to generalized thrombotic microangiopathy\u2014role of acquired ADAMTS13 deficiency in a renal allograft recipient","volume":"6","author":"Ulinski","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0270","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/TP.0b013e31827e31c9","article-title":"Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation","volume":"95","author":"de Vries","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.10.001_bb0275","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1093\/ndt\/gfr436","article-title":"Three kidneys, two diseases, one antibody?","volume":"26","author":"Lorcy","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0280","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s00467-012-2210-0","article-title":"Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case","volume":"27","author":"Gnappi","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0285","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1681\/ASN.2014050429","article-title":"Complement factor C4d is a common denominator in thrombotic microangiopathy","volume":"26","author":"Chua","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0290","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2017.10.001_bb0295","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1046\/j.1600-6143.2003.00222.x","article-title":"Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation","volume":"3","author":"Karthikeyan","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0300","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/MOT.0000000000000074","article-title":"Thrombotic microangiopathy in renal allografts: the diagnostic challenge","volume":"19","author":"Nadasdy","year":"2014","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0305","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/TP.0000000000000200","article-title":"Atypical hemolytic uremic syndrome recurrence after kidney transplantation","volume":"98","author":"Matar","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.10.001_bb0310","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5414\/CNP58077","article-title":"Successful treatment of tacrolimus-associated thrombotic microangiopathy with sirolimus conversion and plasma exchange","volume":"58","author":"Yango","year":"2002","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0315","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0272-6386(96)90468-0","article-title":"Cyclosporine-associated thrombotic microangiopathy\/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation","volume":"28","author":"Young","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2017.10.001_bb0320","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00467-014-3036-8","article-title":"De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus","volume":"30","author":"Cortina","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0325","doi-asserted-by":"crossref","first-page":"E261","DOI":"10.1111\/j.1399-3046.2011.01601.x","article-title":"Successful sirolimus rescue in tacrolimus-induced thrombotic microangiopathy after living-related liver transplantation","volume":"16","author":"Czubkowski","year":"2012","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0330","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0041-1345(03)00614-6","article-title":"De novo hemolytic-uremic syndrome\/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: role of sirolimus","volume":"35","author":"Franco","year":"2003","journal-title":"Transplant Proc"},{"issue":"11","key":"10.1016\/j.trre.2017.10.001_bb0335","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1111\/trf.14263","article-title":"Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy","volume":"57","author":"Epperla","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.trre.2017.10.001_bb0340","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2017.10.001_bb0345","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2017.10.001_bb0350","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/ajt.12589","article-title":"Diagnosis and management of antibody-mediated rejection: current status and novel approaches","volume":"14","author":"Djamali","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0355","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1600-6143.2008.02482.x","article-title":"Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy","volume":"9","author":"Ashman","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0360","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/ctr.12170","article-title":"Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients","volume":"27","author":"Koppula","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0365","doi-asserted-by":"crossref","first-page":"260254","DOI":"10.1155\/2013\/260254","article-title":"Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathy","volume":"2013","author":"Cicora","year":"2013","journal-title":"Case Rep Med"},{"key":"10.1016\/j.trre.2017.10.001_bb0370","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2017.10.001_bb0375","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/nep.12936","article-title":"De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab","volume":"22","author":"Shochet","year":"2017","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.trre.2017.10.001_bb0380","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.transproceed.2016.11.008","article-title":"Eculizumab and Belatacept for de novo atypical hemolytic uremic syndrome associated with CFHR3-CFHR1 deletion in a kidney transplant recipient: a case report","volume":"49","author":"Dedhia","year":"2017","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2017.10.001_bb0385","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/nep.12768","article-title":"Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab","volume":"21","author":"Ikeda","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.trre.2017.10.001_bb0390","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5414\/CN108163","article-title":"Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: a case report","volume":"83","author":"Safa","year":"2015","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.trre.2017.10.001_bb0395","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.transproceed.2011.02.064","article-title":"Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation\u2014a case report","volume":"43","author":"Chandran","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2017.10.001_bb0400","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1097\/TP.0b013e318230c0bd","article-title":"Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab","volume":"92","author":"Wilson","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.10.001_bb0405","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0410","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.transproceed.2012.09.038","article-title":"Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports","volume":"44","author":"Gonzalez-Roncero","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2017.10.001_bb0415","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1542\/peds.2014-2275","article-title":"Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient","volume":"135","author":"Chehade","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.trre.2017.10.001_bb0420","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-6143.2008.02451.x","article-title":"The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection","volume":"9","author":"Locke","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0425","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1111\/j.1600-6143.2010.03191.x","article-title":"Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access","volume":"10","author":"Lonze","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0430","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.transproceed.2012.03.053","article-title":"Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant","volume":"44","author":"Stewart","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2017.10.001_bb0435","article-title":"Eculizumab for the treatment of severe antibody-mediated rejection: a case report and review of the literature","volume":"2016","author":"Tran","year":"2016","journal-title":"Case Rep Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0440","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/TP.0000000000000298","article-title":"Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation","volume":"98","author":"Orandi","year":"2014","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.trre.2017.10.001_bb0445","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/ajt.14001","article-title":"Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial","volume":"17","author":"Kulkarni","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.10.001_bb0450","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/ajt.13168","article-title":"Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1year","volume":"15","author":"Cornell","year":"2015","journal-title":"Am J Transplant"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X17300058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X17300058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T16:05:48Z","timestamp":1760630748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X17300058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0955470X17300058"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2017.10.001","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De novo thrombotic microangiopathy after kidney transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2017.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}